Find News

Filter articles

Applied Filters

Showing 21 to 30 of 1026 results

Janssen seeks to halt generic schizophrenia drug


Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate).

Pfizer sues Teva over arthritis treatment

US17-02-2022Alex Baldwin

Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires.

Judge partially revives California pay-for-delay ban


A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.

Afrigen creates COVID vaccine using Moderna data

South Africa15-02-2022Alex Baldwin

Afrigen Biologics has used the publicly available information relating to Moderna’s COVID-19 vaccine to manufacture its own version of the treatment, which could see testing by the end of this year.

Lupin and Sun settle Bromsite patent suit after ruling

US10-02-2022Alex Baldwin

Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

US08-02-2022Alex Baldwin

AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

Celgene, Dr Reddy's abandon cancer drug patent dispute

US01-02-2022Muireann Bolger

Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

US27-01-2022Muireann Bolger

AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.

Virginia judge says court should deny class cert in Zetia antitrust suit

International27-01-2022Alex Baldwin

A Virginia district court judge has recommended that buyers of cholesterol drug Zetia should not be granted class certification in pay-for-delay litigation against MSD and Glenmark Generics.

Mylan gets green light to challenge Neurim melatonin patent

UK25-01-2022Muireann Bolger

Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Showing 21 to 30 of 1026 results